ABBV vs GS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Goldman Sachs Group, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
The Goldman Sachs Group, Inc. · Financial Services
$923.29
+25.9% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
GS has more upside to fair value
(+25.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GS |
| Current Price |
$261.70 |
$923.29 |
| Fair Value Estimate |
$259.04 |
$1,162.79 |
| Upside to Fair Value |
-1.0%
|
+25.9%
|
| Market Cap |
$462.4B |
$272.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
26.3x
|
| Price / Sales |
7.2x
|
2.3x
|
| Price / FCF |
23.6x
|
—
|
| Revenue Growth YoY |
+10.2%
|
+22.9%
|
| Gross Margin |
71.5%
|
57.3%
|
| Operating Margin |
29.3%
|
24.8%
|
| Return on Equity |
-136.5%
|
17.0%
|
| Dividend Yield |
2.61% |
1.95% |
| FCF Yield |
4.25%
|
—
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Goldman Sachs is a global financial services firm operating four divisions: Investment Banking, Global Markets, Asset Management, and Consumer & Wealth Management, with 46,200 full-time employees and a market cap of $272.38 billion at a current price of $923.29. The business quality is high because of its leading franchise in advisory, underwriting, and trading, evidenced by a 17.0% ROE, a 57.3% …
Accumulation Zones
| Metric |
ABBV |
GS |
| Zone Low |
$194.28 |
$872.09 |
| Zone High |
$220.18 |
$988.37 |
| In Buy Zone? |
No
|
Yes
|